Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

PET imaging in patients with brain metastasis-report of the RANO/PET group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The natural history of Vestibular Schwannoma growth - prospective 40-year data from an unselected national cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sex-specific gene and pathway modeling of inherited glioma risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual Patient Data Meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Norbert Galldiks
  • Karl-Josef Langen
  • Nathalie L Albert
  • Marc Chamberlain
  • Riccardo Soffietti
  • Michelle M Kim
  • Ian Law
  • Emilie Le Rhun
  • Susan Chang
  • Julian Schwarting
  • Stephanie E Combs
  • Matthias Preusser
  • Peter Forsyth
  • Whitney Pope
  • Michael Weller
  • Jörg C Tonn
Vis graf over relationer

Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.

OriginalsprogEngelsk
TidsskriftNeuro-Oncology
Vol/bind21
Udgave nummer5
Sider (fra-til)585-595
Antal sider11
ISSN1522-8517
DOI
StatusUdgivet - 6 maj 2019

Bibliografisk note

© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

ID: 59320346